These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34365867)

  • 1. Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases.
    Campese N; Beatino MF; Del Gamba C; Belli E; Giampietri L; Del Prete E; Galgani A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Neurother; 2021 Sep; 21(9):949-967. PubMed ID: 34365867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease.
    Beatino MF; De Luca C; Campese N; Belli E; Piccarducci R; Giampietri L; Martini C; Perugi G; Siciliano G; Ceravolo R; Vergallo A; Hampel H; Baldacci F
    Expert Rev Mol Diagn; 2022 Apr; 22(4):411-425. PubMed ID: 35443850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases.
    Campese N; Palermo G; Del Gamba C; Beatino MF; Galgani A; Belli E; Del Prete E; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Proteomics; 2021 Jan; 18(1):27-48. PubMed ID: 33545008
    [No Abstract]   [Full Text] [Related]  

  • 4. Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools.
    Paciotti S; Bellomo G; Gatticchi L; Parnetti L
    Front Neurol; 2018; 9():415. PubMed ID: 29928254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial intelligence-coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases.
    Kavungal D; Magalhães P; Kumar ST; Kolla R; Lashuel HA; Altug H
    Sci Adv; 2023 Jul; 9(28):eadg9644. PubMed ID: 37436975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach.
    Del Prete E; Beatino MF; Campese N; Giampietri L; Siciliano G; Ceravolo R; Baldacci F
    J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33187336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.
    Tapia-Arellano A; Cabrera P; Cortés-Adasme E; Riveros A; Hassan N; Kogan MJ
    J Nanobiotechnology; 2024 May; 22(1):248. PubMed ID: 38741193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis.
    Grossauer A; Hemicker G; Krismer F; Peball M; Djamshidian A; Poewe W; Seppi K; Heim B
    Mov Disord Clin Pract; 2023 May; 10(5):737-747. PubMed ID: 37205253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.
    Giampietri L; Belli E; Beatino MF; Giannoni S; Palermo G; Campese N; Tognoni G; Siciliano G; Ceravolo R; De Luca C; Baldacci F
    Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive RT-QuIC Seed Amplification Assays for Disease-Associated Tau, α-Synuclein, and Prion Aggregates.
    Saijo E; Groveman BR; Kraus A; Metrick M; Orrù CD; Hughson AG; Caughey B
    Methods Mol Biol; 2019; 1873():19-37. PubMed ID: 30341601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
    Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
    Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases.
    Palermo G; Mazzucchi S; Della Vecchia A; Siciliano G; Bonuccelli U; Azuar C; Ceravolo R; Lista S; Hampel H; Baldacci F
    Mol Neurobiol; 2020 Nov; 57(11):4667-4691. PubMed ID: 32772223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Conversion Assays Diagnostic for Neurodegenerative Proteinopathies.
    Singh S; DeMarco ML
    J Appl Lab Med; 2020 Jan; 5(1):142-157. PubMed ID: 31811072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteopathic Seed Amplification Assays for Neurodegenerative Disorders.
    Ferreira NDC; Caughey B
    Clin Lab Med; 2020 Sep; 40(3):257-270. PubMed ID: 32718498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the Protein Seeds of Neurodegeneration using Real-Time Quaking-Induced Conversion Assays.
    Manca M; Kraus A
    Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32854212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.
    Baldacci F; Mazzucchi S; Della Vecchia A; Giampietri L; Giannini N; Koronyo-Hamaoui M; Ceravolo R; Siciliano G; Bonuccelli U; Elahi FM; Vergallo A; Lista S; Giorgi FS; Hampel H
    Expert Rev Mol Diagn; 2020 Apr; 20(4):421-441. PubMed ID: 32066283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.